

**BASIC RESEARCH SESSION**

Moderator: Jovana Kovačević

<b>Time (CET, Brussels)</b>	<b>Topic</b>	<b>Speaker</b>	<b>Affiliation</b>	<b>Country</b>
12:30-13:00	Welcome note and Introduction talk (15+15 min)	<b>Organizing Committee Chair: Drenka Trivanović, PhD</b>	<i>Institute for Medical Research, University of Belgrade</i>	<i>Serbia</i>
13:00-13:20	Signals from microenvironment: biomarkers for myeloma bone disease (basic talk) (15+5 min)	<b>Prof. Regina Ebert, PhD</b>	<i>Department of Musculoskeletal Tissue Regeneration, Orthopedic Clinic König-Ludwig-Haus, University of Würzburg</i>	<i>Germany</i>
13:20-13:40	Proteome-based approaches for multiple myeloma research (basic talk) (15+5 min)	<b>Ieronymos Zoidakis, PhD</b>	<i>Biomedical Research Foundation, Academy of Athens, Athens</i>	<i>Greece</i>
13:40-14:00	Bone marrow adipocytes and myeloma (15+5 min)	<b>Zoltán Kellermayer, PhD</b>	<i>University of Pécs Medical School</i>	<i>Hungary</i>
14:00-14:20	Skeletal niche cells in regulating hematopoiesis and bone: cancer cell dormancy in myeloma (basic talk) (15+5 min)	<b>Alanna Green, PhD</b>	<i>Department of Oncology &amp; Metabolism, University of Sheffield, Sheffield</i>	<i>United Kingdom</i>
14:20-14:40	Industrial talk: DXA measurement in myeloma bone disease (10 +5 min)	<b>Tiina Kähkönen, PhD</b>	<i>OncoBone, Ltd</i>	<i>Finland</i>

**BREAK**

**CLINICAL RESEARCH SESSION**

Moderator: Srđa Janković

<b>Time (Central European Time, Brussels) PM</b>	<b>Topic</b>	<b>Speaker</b>	<b>Afiliation</b>	<b>Country</b>
14:50-15:20	Integration of bioinformatics databases on gene-disease relations (20+10 min)	<b>Jovana Kovačević, PhD</b>	<i>Faculty of Mathematics, University of Belgrade</i>	<i>Serbia</i>
15:20-15:40	The role of hematopoietic stem cell transplantation in the time of new immunologic and cellular therapies (clinical talk) (15+5 min)	<b>Jelena Bila, MD, PhD</b>	<i>Clinic of Hematology, University Clinical Center of Serbia, Belgrade</i>	<i>Serbia</i>
15:40-16:00	Transfusion management of multiple myeloma patients (clinical talk)	<b>Dušan Vučetić, MD, PhD</b>	<i>Institute for Transfusiology and Haemobiology, Military Medical Academy, Belgrade</i>	<i>Serbia</i>
16:00-16:20	Chemotherapy for myeloma patients: experience from hematology department (clinical talk) (15+5 min)	<b>Mila Purić, MD</b>	<i>Hematology Divison, Institute for Oncology and Radiology of Serbia, Belgrade</i>	<i>Serbia</i>
16:20-16:40	Immune status of multiple myeloma patients: experience from hematology clinic (clinical talk) (15+5 min)	<b>Sunčica Kapor, MD, PhD</b>	<i>Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje"</i>	<i>Serbia</i>
16:40-17:00	Circulating Tumor Cells in multiple myeloma (clinical talk) (15+5 min)	<b>Nada Kraguljac Kurtović, PhD</b>	<i>Clinic of Hematology, University Clinical Center of Serbia, Belgrade</i>	<i>Serbia</i>
17:00-17:20	Flow cytometry screening of MRD in multiple myeloma patients (clinical talk) (15+5 min)	<b>Dragan Jevremovic, MD, PhD</b>	<i>Division of Hematopathology, Mayo Clinic, Rochester, Minnesota</i>	<i>United States</i>
17:20-17:35	Industrial talk: Innovative anti-myeloma drugs (10+5 min)	<b>Jasmina Cvetkovic, PhD</b>	<i>Pfizer Serbia</i>	<i>Serbia</i>
17:35-17:45	Closing Remarks (15 min)	<b>Organizers</b>		<i>Serbia</i>